Sigma-Tau Pharmaceuticals Revenue and Competitors

sigma-tau was founded at the end of the 1950s and is one of the leading Italian pharmaceutical groups. It employs 2,400 people, 400 of whom work in R&D. Since its creation, the Group has made significant investment in the Research and Development activities. The Group focuses on the following therapeutic areas: cardiovascular, metabolism, central and peripheral nervous system, immunology and oncology. Particular significance in this latter area has “Gimatecan”, a novel anticancer compound. A major agreement was signed in 2003 with the Swiss multinational drug company Novartis, which acquired the worldwide development and marketing rights for Gimatecan from sigma-tau.Currently, sigma-tau’s portfolio includes 48 projects in several therapeutic areas; 10 NCEs (New Chemical Entities) are under investigation; clinical trials are being conducted in 32 different indications with 16 proprietary molecules, 13 of which are “new and original”. sigmataus particularly proud of its R&D efforts in the area of “Rare Diseases” which being intensively developed by its US subsidiary, sigma-tau Pharmaceuticals, Inc.The Group, headquartered in Pomezia (Rome), has subsidiaries in France, Switzerland, the Netherlands, Germany, the USA (Gaithersburg, Maryland), as well as in Spain and Sudan, where the Group runs two production facilities. Finally, sigma-tau has recently established cooperationsin China for the worldwide development of an anti-malarial drug deriving from Chinese traditional medicine.